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Thomson et al. use TRAP-seq to identify
excessive translation of muscarinic
receptor M4 in Fmr1
/y neurons.
Surprisingly, enhancement rather than
inhibition of M4 corrects neurological
Fmr1/y phenotypes. This suggests that
elevated translation of certain mRNAs in
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Excessive mRNA translation downstream of group I
metabotropic glutamate receptors (mGlu1/5) is a
core pathophysiology of fragile X syndrome (FX);
however, the differentially translating mRNAs that
contribute to altered neural function are not known.
We used translating ribosome affinity purification
(TRAP) and RNA-seq to identify mistranslating
mRNAs in CA1 pyramidal neurons of the FX mouse
model (Fmr1/y) hippocampus, which exhibit exag-
geratedmGlu1/5-induced long-term synaptic depres-
sion (LTD). In these neurons, we find that the Chrm4
transcript encoding muscarinic acetylcholine recep-
tor 4 (M4) is excessively translated, and synthesis of
M4 downstream of mGlu5 activation is mimicked
and occluded. Surprisingly, enhancement rather
than inhibition of M4 activity normalizes core pheno-
types in the Fmr1/y, including excessive protein
synthesis, exaggerated mGluR-LTD, and audiogenic
seizures. These results suggest that not all exces-
sively translated mRNAs in the Fmr1/y brain are
detrimental, and some may be candidates for
enhancement to correct pathological changes in
the FX brain.
INTRODUCTION
Several genetic mutations that affect neuronal protein synthesis
have been linked to the development of autism and intellectual
disability (ASD/ID) (Kelleher and Bear, 2008; Louros and Oster-
weil, 2016). Fragile X syndrome (FX), a prominent single-gene
cause of ASD/ID, arises from mutations in the FMR1 gene that
encodes the protein synthesis repressor fragile Xmental retarda-
tion protein (FMRP) (Ashley et al., 1993). In hippocampal CA1,550 Neuron 95, 550–563, August 2, 2017 ª 2017 The Author(s). Publi
This is an open access article under the CC BY license (http://creativeFMRP is synthesized at synapses by activation of group I metab-
otropic glutamate receptors (mGlu1/5), where it acts as a nega-
tive regulator of the mRNA translation supporting long-term
synaptic depression (LTD) (Bear et al., 2004; Weiler et al.,
1997). In the FX mouse model (Fmr1/y), loss of FMRP leads to
excessive protein synthesis downstream of mGlu1/5 activation,
and consequently, mGluR-LTD is exaggerated and no longer
dependent upon new protein synthesis (Huber et al., 2002;
Nosyreva and Huber, 2006).
According to the mGluR theory of fragile X, excessive transla-
tion underlies several neurological pathologies in FX, and
numerous studies support this interpretation (Bear et al., 2004;
Stoppel et al., 2017). Excessive protein synthesis has been
observed in multiple brain regions of the Fmr1/y mouse (Do¨len
et al., 2007; Osterweil et al., 2010; Qin et al., 2005), and several
strategies that reduce protein synthesis have been shown to cor-
rect pathological phenotypes (Bhattacharya et al., 2016; Gross
et al., 2015; Henderson et al., 2012; Liu et al., 2012; Michalon
et al., 2012; Osterweil et al., 2013). Although there have been
excellent studies identifying FMRP target mRNAs (Brown et al.,
2001; Darnell et al., 2011), as well as proteins differentially ex-
pressed in the Fmr1/y brain (Klemmer et al., 2011; Liao et al.,
2008; Tang et al., 2015), there is little known about the identities
of the mistranslating mRNAs that contribute to neurological
deficits in FX. If aberrant mRNA translation is indeed a core path-
ophysiology, then the challenge becomes isolating and interpret-
ing the changes in translation that result in altered function.
In this study, we employed a combination of cell-type-specific
translating ribosome affinity purification (TRAP) and RNA
sequencing (RNA-seq) to identify differentially translating
mRNAs in CA1 pyramidal neurons of the Fmr1/y hippocampus
(Heiman et al., 2008). We focused on CA1 pyramidal neurons
based on work showing that excessive translation in these
neurons leads to functional disruption, namely the exaggeration
of mGluR-LTD in the Fmr1/y mouse (Nosyreva and Huber,
2006). This first cell-type-specific translation analysis identified
121 differentially translating mRNAs in Fmr1/y CA1 neurons.
Interestingly, the muscarinic acetylcholine receptor (mAChR)shed by Elsevier Inc.
commons.org/licenses/by/4.0/).
signaling pathway is the most significantly changed gene
category, with the Chrm4 mRNA encoding muscarinic subtype
M4 significantly overexpressed in the Fmr1
/y. Further experi-
ments confirmed the over-translation of Chrm4 and subsequent
overexpression of M4 in Fmr1
/y hippocampus. Based on these
results, we examined whether inhibition of M4 could correct
pathological changes in the Fmr1/y brain. To our surprise,
we find that the opposite strategy, an enhancement of M4
using the highly specific positive allosteric modulator (PAM)
VU0152100, normalizes excessive protein synthesis and exag-
gerated mGluR-LTD in the Fmr1/y hippocampus. Furthermore,
systemic injection of VU0152100 significantly reduces the inci-
dence of audiogenic seizures (AGS) in Fmr1/y mice. These re-
sults suggest that not all excessively translated mRNAs in the
Fmr1/y brain are contributing to pathological changes. Instead,
one of the most significantly over-translated mRNAs in Fmr1/y
CA1 neurons encodes a protein that should be positively modu-
lated rather than inhibited to correct brain function.
RESULTS
Isolation of Translating mRNAs from Hippocampal CA1
Pyramidal Neurons Using TRAP
InFmr1/yCA1, excessive translation contributes to the exagger-
ation of mGluR-LTD (Huber et al., 2002). To isolate differentially
translating mRNAs specifically from CA1 pyramidal neurons,
we used a TRAP strategy that allows for cell-type-specific isola-
tion of translating mRNAs using bacterial artificial chromosome
(BAC) transgenic mouse lines engineered to express a GFP-
tagged L10a ribosomal subunit in select cell populations (Heiman
et al., 2008). The association of the L10a subunit with the 60S
large ribosomal subunit allows for the enrichment of translating
mRNAs (Heiman et al., 2008; Katz et al., 2016). For our study,
we used a BAC transgenic line that shows a CA1 pyramidal-spe-
cific expression ofGFP-L10awithin the hippocampus (referred to
as CA1-TRAP) (Doyle et al., 2008; Tao et al., 2016). Confocal im-
aging of coronal brain sections from this CA1-TRAP mouse
confirms an expression of GFP-L10a within both the soma and
dendrites of pyramidal neurons in the CA1 region (Figure 1A).
Analysis of GFP-expressing (GFP+) cells isolated by fluores-
cence-activated cell sorting (FACS) reveals an enrichment of
the CA1 pyramidal neuron marker Wfs1 (*p < 0.0001) and the
excitatory neuron marker Camk2a (*p = 0.0046) as compared
to total hippocampal cells. In contrast, the glial marker Gfap
is depleted (*p = 0.0218; Figure 1B). This confirms that the
GFP-L10a-expressing cells are indeed CA1 pyramidal neurons.
To ensure that we could isolate CA1-specific translatingmRNAs,
we performed TRAP immunoprecipitations (IPs) from hippo-
campi isolated from CA1-TRAP mice using previously estab-
lished protocols (Heiman et al., 2008) (Figure 1C). Ribosome-
bound transcripts were analyzed using RNA-seq, and the
identified genes were compared to previously published data-
sets from cerebellar Bergmann glia (BG), Purkinje cells (PCs),
and granule cells (GCs) (Melle´n et al., 2012). The results of these
comparisons show a significant enrichment of CA1 pyramidal
neuron markers in the translating ribosome fraction (Figure 1D;
Figure S1). These results confirm that mRNAs isolated in the
CA1-TRAP IP originate from CA1 pyramidal neurons.RNA-Seq Identifies Differentially Translating mRNAs in
Fmr1–/y CA1 Pyramidal Neurons
To identify differentially translating mRNAs in Fmr1/y CA1 neu-
rons, we compared Fmr1/y (knockout [KO]) and wild-type (WT)
littermate mice, each heterozygous for the CA1-TRAP trans-
gene. All experiments were performed with the experimenter
blind to genotype. In order to confirm that changes seen in
Fmr1/y TRAP-bound mRNAs are consistent with changes
seen using other methodologies, we measured the expression
of Camk2a, previously shown to be over-translated in multiple
studies (Darnell et al., 2011; Osterweil et al., 2010; Zalfa et al.,
2003). Our results show a significant enrichment of Camk2a in
the Fmr1/y CA1-TRAP fraction (*p = 0.0004) (Figure 1E). In
contrast, total Camk2a expression is not elevated in FACS-iso-
lated CA1 pyramidal neurons from Fmr1/y hippocampus, sug-
gesting that changes seen in the TRAP fraction are not due to
changes in the transcription of Camk2a (Figure 1E).
After verifying that the Fmr1/y CA1-TRAP reflects previously
reported changes in translation, we performed RNA-seq on six
sets of Fmr1/y and WT CA1-TRAP littermates (see STAR
Methods). Hippocampi were isolated from Fmr1/y andWT litter-
mates at a juvenile age (postnatal days 25–32) when the exag-
gerated mGluR-LTD phenotype is observed (Nosyreva and
Huber, 2006). RNA was isolated from both the TRAP fraction
and the starting Input, and samples were processed for RNA-
seq according to established protocols (see STAR Methods).
Differential gene expression was determined using DESeq2 at
the default false discovery rate (FDR) of 0.1, consistent with pre-
vious studies (Cho et al., 2015; Tao et al., 2016). Our results show
that 121 genes are differentially expressed in the Fmr1/y CA1-
TRAP fraction (Figure 1F). Themajority of differentially translating
transcripts are increased in the Fmr1/y versus WT (Table S1);
however, a significant number are also decreased (Table S2).
In contrast to the ribosome-bound TRAP fraction, a comparison
of WT and Fmr1/y Input fractions reveals only three differentially
expressed genes (Figure 1F). This is consistent with the
observed increase in translation, but not transcription, seen in
the Fmr1/y hippocampus (Muddashetty et al., 2007; Osterweil
et al., 2010).
FMRP Target mRNAs Are Downregulated in Fmr1–/y
Hippocampus
The number of mRNA targets of FMRP is estimated to be well
over 800, and it is believed that many of these are translationally
repressed when bound to FMRP (Darnell et al., 2011). However,
it is not clear how many of these mRNAs are over-translating in
the Fmr1/y brain. Our analysis of differentially translating
mRNAs identified only three verified FMRP targets (Cacna1d,
Arhgef17, and Pcdhgc5), and all are downregulated in the
Fmr1/y TRAP (Table S2) (Darnell et al., 2011). This surprising
result motivated us to investigate the global expression differ-
ence in all FMRP target mRNAs in both the Input (i.e., total
hippocampal mRNA) and CA1-TRAP fractions of the Fmr1/y
hippocampus as compared to WT (Figure 2A). To do this, we
compared the differential expression of FMRP target mRNAs
to all genes expressed at the same level of abundance (Fig-
ure 2B). Interestingly, a cumulative distribution of FMRP targets
in the differentially expressed population shows a significantNeuron 95, 550–563, August 2, 2017 551
Figure 1. TRAP-Seq Identifies Differentially Translating mRNAs in Fmr1–/y CA1 Pyramidal Neurons
(A) Confocal images show selective expression of GFP-L10a in pyramidal neurons of the CA1 region.
(B) GFP-positive (GFP+) cells in CA1-TRAP hippocampus are enriched for CA1 neuronal markers (Camk2a: GFP 0.683 ± 0.05, GFP+ 1.200 ± 0.138, *p = 0.0046,
n = 12; Wfs1: GFP 0.370 ± 0.104, GFP+ 1.781 ± 0.224, *p < 0.0001, n = 9) and depleted of glial markers (Gfap: GFP 1.784 ± 0.650, GFP+ 0.054 ± 0.022,
*p = 0.0218, n = 12) compared to all cells.
(C) Schematic representation of TRAP shows isolation of translating ribosomes (IP) from Input using anti-GFP coated beads.
(D) Differentially expressed genes in CA1-TRAP versus Bergmann glia (BG)-specific TRAP are enriched in CA1 neuronal markers according to the Allen Brain Atlas
enrichment algorithm.
(E)Camk2a is significantly increased in Fmr1/y versusWTCA1-TRAP IP (WT = 1.00 ± 0.037, KO = 1.26 ± 0.054, *p = 0.0004, n = 14). TotalCamk2a is equivalent in
Fmr1/y and WT FACs-isolated CA1 pyramidal neurons (WT = 1.00 ± 0.059, KO = 0.855 ± 0.047, p = 0.0734, n = 9).
(F) TRAP-seq analysis reveals differential expression of 121 genes in the IP fraction and 3 genes in the Input fraction (FDR < 0.1). n = number of littermate pairs.
Error bars indicate SEM.shift toward downregulation (Kolmogorov-Smirnov [K-S] test
*p = 9.23 3 1014) (Figure 2C). The same significant shift was
seen when the FMRP target list was compared to five randomly
generated gene sets of the same size (Figure S2). This indicates a
subtle reduction in the expression of FMRP targets in the Fmr1/y
hippocampal mRNA population when compared to WT. To
examine whether the reduction in FMRP target expression was
reflected in the translating ribosome fraction, we repeated this552 Neuron 95, 550–563, August 2, 2017analysis using CA1-TRAP samples. The results show the same
difference in the distribution of FMRP targets versus WT (K-S
test *p = 4.863 1013) (Figure 2D; Figure S2). Thus, the reduced
expression of FMRP targets in the total Fmr1/y mRNA Input is
mirrored in the CA1-TRAP fraction. The conclusion from our
analysis is that FMRP target mRNAs are not necessarily enriched
in the translating ribosome fraction of the Fmr1/y hippocampus
at this age.
Figure 2. Differentially Translated mRNAs in Fmr1–/y CA1 Include FMRP Targets and mAChR Transcripts
(A) Differential expression analysis shows gene changes in WT versus Fmr1/y Input fraction, with FMRP targets highlighted in blue.
(B) FMRP targets were compared to differentially expressed (total) genes with the same level of abundance (normalized count between 102.5 and 104.25).
(C and D) A cumulative distribution of FMRP targets shows a significant shift toward downregulation when compared to the distribution of total differentially
expressed genes with the same level of abundance in both Input (C) and CA1-TRAP (D) fractions (K-S test, p = 9.23 3 1014, p = 4.86 3 1013).
(E) Pfam analysis of enriched protein families reveals that six out of eight pClans enriched in the differentially expressed (DE) Fmr1/yCA1-TRAP gene list overlap
with pClans enriched in the CA1-adjusted FMRP target list.
(F) Heatmap shows the fold change of differentially expressed genes in each pair of Fmr1/y versus WT (IP and Input fractions).
(G) GO analysis identifies G-protein-coupled acetylcholine receptor signaling pathway as the most enriched functional category in the upregulated Fmr1/yCA1-
TRAP gene list.
(H) Drug gene interaction database reveals that Chrm4 is the most amenable target pharmacologically. Upregulated genes are highlighted in green, and
downregulated genes are highlighted in red. n = number of littermate pairs. Error bars indicate SEM.
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One possibility suggested by our findings is that differentially
translating mRNAs in the juvenile Fmr1/y hippocampus are
not necessarily reflective of a proximal loss of FMRP, but rather
they represent a homeostatic shift that has developed in
response to an early loss of FMRP. We thus wondered whether
the differentially translating mRNAs that we identified were
compensating for the downregulated FMRP targets. To investi-
gate this, we examined whether the differentially expressed tran-
scripts in the Fmr1/y CA1-TRAP encoded proteins similar to
those encoded by FMRP targets. To sort these transcripts by
function, we used a Pfam analysis to categorize differentially ex-
pressed mRNAs and FMRP targets into protein clans (pClans)
(Finn et al., 2016). The enrichment of the pClans in each list
was determined using a background list of CA1 specific genes
(see STAR Methods). Our analysis revealed that of the eight
pClans enriched in the list of differentially expressed transcripts,
six of them were enriched in the FMRP target list (Figure 2E;
Table S3), indicating that the majority of differentially translating
mRNAs in Fmr1/y CA1 neurons are functionally similar to FMRP
targets. It is possible that these changes are compensatory
adaptations to the original loss of FMRP and subsequent dysre-
gulation of FMRP target mRNAs.
Muscarinic Acetylcholine Receptors Are Excessively
Translated in Fmr1–/y CA1 Pyramidal Neurons
A major aim of our TRAP-seq experiments was to identify the
excessively translating mRNAs in Fmr1/y CA1 that underlie
altered function. We began by performing an unbiased gene
ontology (GO) analysis to determine whether any particular
gene category was enriched in the differentially translating pop-
ulation isolated from the six sets of Fmr1/y CA1-TRAP hippo-
campi. Separate analyses were performed for all differentially
expressed transcripts, upregulated transcripts, and downregu-
lated transcripts in the Fmr1/y CA1-TRAP (Figure 2F; Tables
S4–S6). Interestingly, our analysis of both total transcripts and
upregulated transcripts revealed a significant enrichment of
the G-protein-coupled (GPC) acetylcholine receptor (mAChR)
signaling pathway (Figure 2G; Tables S4 and S5). Specifically,
the Chrm4 and Chrm5 genes encoding the M4 and M5 receptors
were upregulated in the Fmr1/y CA1-TRAP samples (Tables S4
and S5). This result was particularly interesting in light of thewell-
known role ofmAChRs, includingM4, in themodulation of synap-
tic plasticity and excitability in the hippocampus (Bubser et al.,
2012). In addition to this analysis, we also wondered whether
any of the differentially expressed mRNAs in the Fmr1/y CA1-
TRAP encoded targets for pharmacological intervention. We
investigated this using the recently developed Drug Gene
Interaction database (DGIdb; http://dgidb.genome.wustl.edu/),
which ranks gene sets based on number of known drug interac-
tions (Griffith et al., 2013). The results identifiedChrm4 as the top
candidate in our list (Figure 2H). Thus, the muscarinic receptor
family represented both the most significantly overexpressed
gene category in the Fmr1/yCA1-TRAP and the most amenable
to pharmacological manipulation.
The mAChR family is comprised of five subtypes, which are
coupled to either the Gq-PLC (M1, M3, and M5) or Gi/o/Gs-
cAMP (M2 and M4) signaling pathways (Kruse et al., 2014). Of
these subtypes, M1, M4, and M3 are the most predominantly ex-554 Neuron 95, 550–563, August 2, 2017pressed in the hippocampus (Zang andCreese, 1997). To assess
the translation of these receptors in Fmr1/y versus WT CA1, we
performed additional TRAP experiments and measured the
levels of Chrm4, as well as of Chrm1 and Chrm3, using quantita-
tive PCR (qPCR). Our results revealed a significant overexpres-
sion of Chrm4 (*p = 0.0044) and Chrm1 (*p < 0.0001), but not
Chrm3, in the Fmr1/y CA1-TRAP IP (Figure 3A). Although we
also validated the increased expression of Chrm5 in the
Fmr1/y CA1-TRAP (*p = 0.041), this transcript is much less
abundant in the hippocampus (Figure S3). We therefore focused
our further analyses on the M1, M3, and M4 subtypes.
To determine whether the increased expression of Chrm4 and
Chrm1 in the Fmr1/y TRAP was due to a change in the basal
expression of these transcripts in CA1 pyramidal neurons, we
examined total mRNA expression in FACS-isolated GFP-L10a-
expressing neurons. qPCR analyses revealed no elevation in
Chrm4, Chrm1, or Chrm3 transcripts in these cells, suggesting
that the increased expression of these transcripts in the trans-
lating ribosome fraction is not driven by an underlying change
in transcription (Figure 3B). Next, we investigated whether the
increased translation of Chrm4 and Chrm1 resulted in an
increased expression of M4 and M1 receptors in the Fmr1
/y hip-
pocampus. Consistent with our previous experiments using
TRAP, quantitative immunoblotting of hippocampal slice ho-
mogenate shows a significant increase in M4 expression in the
Fmr1/y hippocampus (*p = 0.0186; Figure 3C). This increase is
also seen in synaptoneurosome fractions isolated from Fmr1/y
hippocampus (*p = 0.0203), suggesting thatM4 is overexpressed
at the synapse. Similar to the CA1-TRAP results, no change was
observed in the expression of M3 in Fmr1
/y hippocampal ho-
mogenates (Figure 3D). Interestingly, the expression of M1 was
also not significantly changed in Fmr1/y hippocampal homoge-
nate (Figure 3E) despite the increase in Chrm1 observed in
Fmr1/y CA1-TRAP. These results suggested that either the
increased translation of Chrm1 did not result in M1 overexpres-
sion or the increase in M1 was occluded by the presence of
other cell types in a whole hippocampal homogenate. To distin-
guish between these possibilities, we used a combination of
FACS and immunostaining to measure the levels of M4, M1,
and M3 selectively in CA1 pyramidal neurons isolated from the
hippocampus. Neurons from CA1-TRAPWT and Fmr1/y hippo-
campi were dissociated and immunostained for M4, M1, or M3
using Alexa 594-conjugated secondary antibodies, and the
expression levels for all three receptors in the GFP+ cell popula-
tion were determined by quantitative fluorescence measure-
ments (see STAR Methods; Figure 3F). Supporting our TRAP
results, we find a significant increase in the expression of M4
and M1, but not M3, in CA1 neurons isolated from the Fmr1
/y
hippocampus (M4 *p = 0.0389, M1 *p = 0.0092, M3 p = 0.547; Fig-
ure 3G). These results confirm that the over-translation of Chrm4
andChrm1 leads to an overexpression of M1 andM4 receptors in
Fmr1/y CA1 pyramidal neurons.
M4 Is Translated Downstream of mGlu5 Activation
Protein synthesis downstream of mGlu1/5 is elevated in the
Fmr1/y brain, and this occludes further translation (Bassell
and Warren, 2008; Osterweil et al., 2010). We thus wondered
whether the translation of Chrm4 and Chrm1 was stimulated
Figure 3. M1 and M4 Are Excessively Synthesized and Overexpressed in Fmr1
–/y CA1 Pyramidal Neurons
(A) Chrm4 and Chrm1, but not Chrm3, are enriched in the Fmr1/y CA1-TRAP IP (Chrm4: WT = 1.00 ± 0.124, KO = 1.72 ± 0.195, *p = 0.0044, n = 14; Chrm1:
WT = 1.00 ± 0.062, KO = 1.47 ± 0.079, *p < 0.0001, n = 14; Chrm3: WT = 1.00 ± 0.085, KO = 1.184 ± 0.073, p = 0.192, n = 10).
(B) Total mRNA levels of Chrm4, Chrm1 and Chrm3 are unchanged in FACS-isolated Fmr1/y CA1 pyramidal neurons (Chrm4: WT = 1.00 ± 0.209, KO = 0.98 ±
0.154, p = 0.926, n = 9; Chrm1: WT = 1.00 ± 0.150, KO = 0.87 ± 0.185, p = 0.602, n = 11; Chrm3: WT = 1.00 ± 0.232, KO = 1.14 ± 0.230, p = 0.668, n = 8).
(C) Immunoblotting shows overexpression of M4 protein in hippocampal slice homogenates (WT = 100% ± 5.7%, KO = 121% ± 5.7%, *p = 0.0186, n = 12) and
synaptoneurosomes (WT = 100% ± 7.10%, KO = 121% ± 6.89%, *p = 0.0203, n = 9).
(D and E) Hippocampal slice homogenates show no difference in M1 (D) (WT = 100%± 2.5%, KO = 105%± 2.5%, p = 0.129, n = 12) or M3 (E) (WT = 100%± 9.5%,
KO = 98% ± 12.9%, p = 0.94, n = 9) expression.
(F) Schematic shows steps for FACS immunostaining.
(G) FACS-immunostaining reveals significant increase in the expression of M4 and M1 (M4: WT = 0.925 ± 0.045, KO = 1.075 ± 0.045, *p = 0.0389, n = 6;
M1: WT = 0.920 ± 0.002, KO = 1.080 ± 0.046, *p = 0.0092, n = 6), but not M3 (WT = 0.962 ± 0.07, KO = 1.038 ± 0.1011 p = 0.547, n = 7), in Fmr1
/y CA1 pyramidal
neurons. n = number of littermate pairs. Error bars indicate SEM.bymGlu1/5 activation andwhether this is saturated in the Fmr1
/y
hippocampus. To test this, we prepared hippocampal slices
from WT CA1-TRAP mice and stimulated them with 50 mM of
the mGlu1/5 agonist S-3,5-Dihydroxyphenylglycine (S-DHPG) in
a manner that induces mGluR-LTD (Figure 4A). To ensure thatour assay accurately reflected mGlu1/5-stimulated translation,
we quantified the levels of mRNA encoding the cytoskeletal
plasticity protein Arc, which is translated in response to DHPG
stimulation and induction of LTD in hippocampal CA1 (Waung
et al., 2008). Consistent with an increase in translation, we seeNeuron 95, 550–563, August 2, 2017 555
Figure 4. M4 Synthesis Downstream of
mGlu5 Is Mimicked and Occluded in the
Fmr1–/y Hippocampus
(A) Time course for DHPG stimulation experi-
ments.
(B) Analysis of transcripts encoding hippocampal
mAChR subunits reveals a striking upregulation of
Chrm4 mRNA in CA1-TRAP IP after mGlu1/5
stimulation (Veh = 1.00 ± 0.12, DHPG = 1.72 ±
0.23, *p = 0.0047, n = 15), with no changes seen in
Chrm1 or Chrm3 (Chrm1: Veh = 1.00 ± 0.07,
DHPG = 1.03 ± 0.06, p = 0.75, n = 16; Chrm3:
Veh = 1.00 ± 0.12, DHPG = 0.82 ± 0.09, p = 0.209,
n = 14).
(C) DHPG stimulation of WT slices shows dramatic
increase in Chrm4 mRNA in the TRAP IP fraction.
In Fmr1/y slices, Chrm4 mRNA is already signifi-
cantly elevated in the TRAP IP and does not
increase further with mGlu1/5 activation (WT
vehicle = 1.00 ± 0.24, WT DHPG = 2.13 ± 0.41, KO
vehicle = 2.28 ± 0.43, KO DHPG = 2.34 ± 0.44,
ANOVA genotype *p = 0.03, treatment *p = 0.048,
WT versus KO veh *p = 0.03, KO veh versus DHPG
p > 0.999, n = 7). Chrm1 mRNA is significantly
elevated in the Fmr1/y CA1-TRAP IP, but DHPG
does not increase Chrm1 in either WT or Fmr1/y
CA1-TRAP IPs (WT vehicle = 1.00 ± 0.09, WT
DHPG = 1.13 ± 0.08, KO vehicle = 1.50 ± 0.13, KO
DHPG = 1.47 ± 0.16, ANOVA genotype *p = 0.005,
treatment p = 0.753, WT versus KO veh *p = 0.04,
WT veh versus DHPG p = 0.944, n = 7). Chrm3
mRNA is neither increased in the Fmr1/y CA1-
TRAP IP nor elevated with DHPG (WT veh = 1.00 ±
0.14, WT DHPG, = 1.029 ± 0.18, KO veh = 0.946 ±
0.19, KO DHPG = 1.09 ± 0.19, ANOVA genotype
p = 0.97, treatment p = 0.55, n = 7).
(D) Immunoblotting shows a robust increase in M4
expression in WT slices after 5 min of DHPG
stimulation, which is maintained at 30 min and
60 min post-stimulation. In contrast, the elevated
expression of M4 in Fmr1
/y slices is not further
increased with DHPG stimulation (WT vehicle =
100% ± 6.63%, WT DHPG 5 min = 159.59% ±
9.37%, WT DHPG 30 min = 131.09% ± 13.23%,
WT DHPG 60 min = 141.66% ± 12.08%, KO
vehicle = 132.70% ± 7.31%, KO DHPG 5 min =
146.95% ± 7.94% KO DHPG 30 min = 131.04% ±
13.01%, KO DHPG 60 min = 155.75% ± 10.28%,
ANOVA treatment 3 genotype *p = 0.037, n = 7).
(E) Time course for MTEP slice experiments.
(F) Incubation with 10 mMMTEP reduces Chrm4 in
the Fmr1/y CA1-TRAP to WT levels (WT vehicle =
1.00 ± 0.112, WT MTEP = 1.48 ± 0.230,
KO vehicle = 2.63 ± 0.352, KO MTEP = 1.63 ±
0.161, ANOVA genotype *p = 0.0014, treatment
p = 0.1923, genotype 3 treatment *p = 0.0119,
WT veh versus KO veh *p = 0.0024, WT veh
versus WT MTEP p = 0.306, KO veh versus KO
MTEP *p = 0.0289, WT MTEP versus KO MTEP
p = 0.880, n = 8).
(G) Immunoblotting shows a significant reduction in M4 expression in MTEP-treated Fmr1
/y slices (WT vehicle = 100% ± 9.7%, WT MTEP = 97% ± 5.4%,
KO vehicle = 181% ± 32.6%, KOMTEP = 103%± 14.1%, ANOVA genotype *p = 0.034, WT veh versus KO veh *p = 0.0181, KO veh versus KOMTEP *p = 0.0145,
n = 6). n = number of littermate pairs. Error bars indicate SEM.
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Figure 5. Enhancement ofM4Normalizes Excessive Protein Syn-
thesis in the Fmr1–/y Hippocampus
(A) Time course for metabolic labeling experiments.
(B) Treatment with the M4 antagonist PD 102807 (0.5 mM or 1 mM) signifi-
cantly increases protein synthesis in both WT and Fmr1/y slices (WT
vehicle=100%±1.66%,WTPD0.5mM=111.35%±7.16%,WTPD1mM=
136% ± 7.17%, KO vehicle = 114.59% ± 4.77%, KO PD 0.5 mM =
120.29%±5.02%,KOPD1mM=129.05%±5.40%,ANOVA treatment *p<
0.0001,WTveh versusKOveh *p= 0.0379,WTveh versusWTPD1 mM*p=
0.0009, KO veh versus KO PD 1 mM *p = 0.0065, n = 8). Example autora-
diograph of slice homogenates shows upregulation of 35S-labeled proteins
with M4 antagonist. Total protein stain of the same blot is shown for
comparison.
(C) Enhancement of M4 with VU0152100 (5 mM) results in selective
reduction of protein synthesis in the Fmr1/y hippocampus, but no change
in WT (WT veh = 100% ± 3.12%, KO veh = 114.2% ± 3.47%, WT VU =
101.7% ± 2.33%, KO VU = 101.3% ± 3.05%, ANOVA genotype 3
treatment *p = 0.0456, WT veh versus VU p = 0.6580, KO veh versus VU
*p = 0.013, n = 16). Example autoradiograph shows a reduction of
35S-labeled proteins in Fmr1/y slices upon incubation with M4 PAM. Total
protein stain of the same blot is shown for comparison. n = number of
littermate pairs. Error bars indicate SEM.a significant increase in Arc mRNA in TRAP IPs isolated from
DHPG-stimulated slices versus unstimulated controls (*p =
0.016; Figure S4). Next, we examined whether DHPG lead to a
similar recruitment of mAChR mRNAs to the ribosome-bound
TRAP IP. Interestingly, our results show a robust increase in
the expression of Chrm4, but not Chrm1 or Chrm3, in the
TRAP IP fraction uponDHPG stimulation (*p = 0.0047; Figure 4B).
No changes were seen in the corresponding Input fractions.
These results show that Chrm4 is selectively translated down-
stream of mGlu1/5 activation in CA1 pyramidal neurons.
To observewhether DHPGcould increaseChrm4 translation in
theFmr1/y, we repeated our experiments onhippocampal slices
from Fmr1/y and WT littermates. Our results reveal that while
DHPG increases Chrm4 in WT (*p = 0.0047), it fails to do so in
the Fmr1y slices where it is already elevated (WT versus KO
veh *p = 0.048; KO veh versus DHPG p > 0.999; Figure 4C).
Consistent with our previous experiments, Chrm1 mRNA is en-
riched in the Fmr1/y TRAP pulldown (*p = 0.046) but does not
change with DHPG stimulation in either WT or Fmr1/y slices.
Chrm3 mRNA is neither increased in the Fmr1/y CA1-TRAP
nor changed with DHPG (Figure 4C). To determine whether the
increased translation of Chrm4 upon DHPG stimulation leads to
an increased expression of the M4 receptor, we measured the
expression of M4 in hippocampal slices after the 5 min of DHPG
stimulation and at 30 min and 60 min post-stimulation. This anal-
ysis reveals that mGlu1/5 activation in WT slices results in a
remarkable increase inM4 expression, which is observed as early
as 5 min post-stimulation (*p = 0.0001), and remains elevated at
30min (*p = 0.047) and 60min (*p = 0.0051) post-stimulation (Fig-
ure 4D; Figure S5). In contrast, the increased expression of M4
observed in Fmr1/y slices (*p = 0.022) remains unchanged with
DHPG stimulation (Figure 4D; Figure S5). Thus, like global protein
synthesis, the production of M4 downstream of mGlu1/5 activa-
tion is mimicked and occluded in Fmr1/y hippocampus.
Previouswork shows that the exaggerated protein synthesis in
the Fmr1/y hippocampus is sensitive to acute antagonism ofmGlu5 (Osterweil et al., 2010). To investigate whether antago-
nism of mGlu5 could reduce the excess translation of M4,
we incubated hippocampal slices in the selective mGlu5 antago-
nist 3-((2-Methyl-1,3-thiazol-4-yl)ethynyl)pyridine hydrochloride
(MTEP) (Figure 4E) (Cosford et al., 2003). Our results show that
application of 10 mM MTEP is sufficient to significantly reduce
the level of Chrm4 in Fmr1/y CA1-TRAP to WT levels (ANOVA
genotype 3 treatment *p = 0.0119; KO veh versus KO MTEP
*p = 0.0289; n = 8) (Figure 4F). To examine whether the reduction
inChrm4 translation was reflected in a reduced expression in M4
protein, we performed quantitative immunoblotting of MTEP-
treated slices. Consistent with our TRAP results, these experi-
ments show that MTEP reduces M4 expression in the Fmr1
/y
hippocampus to WT levels (ANOVA genotype *p = 0.034; KO
veh versus KO MTEP *p = 0.0145; n = 6) (Figure 4G; Figure S5).
These findings confirm that the excess synthesis of M4 in the
Fmr1/y hippocampus is downstream of mGlu5 activation.
Positive Modulation of M4 Corrects Excessive Protein
Synthesis in the Fmr1–/y Hippocampus
The excessive translation of M4 in the Fmr1
/y and correction by
mGlu5 antagonism suggested that this receptor could be
contributing to pathological changes in the Fmr1/y brain. To
investigate this idea, we tested the effect of M4 antagonism on
the excessive protein synthesis phenotype in the Fmr1/y hippo-
campus using an established metabolic labeling assay (see
STAR Methods) (Osterweil et al., 2010). Briefly, hippocampal
slices were prepared from Fmr1/y and WT littermates and
new protein synthesis was measured in the presence of vehicle
or the selective M4 antagonist PD 102807 by incorporation of
35S-methionine/cysteine (Figure 5A) (Olianas and Onali, 1999).
Surprisingly, our results showed that application of PD 102807,
at doses previously shown to be selective for M4, caused a sig-
nificant increase in protein synthesis in both WT and Fmr1/y
slices (ANOVA treatment *p < 0.0001; WT veh versus KO veh
*p = 0.0379; WT veh versus WT PD 1 mM *p = 0.0009, KONeuron 95, 550–563, August 2, 2017 557
Figure 6. M4 PAM Corrects Exaggerated
mGluR-LTD in the Fmr1–/y Mouse
(A) Measurement of mGluR-LTD in hippocampal
CA1 shows a significant elevation in vehicle-
treated Fmr1/y versus WT (WT = 84.7% ± 3.4%,
n = 16, KO = 71.2% ± 2.47%, n = 15, *p = 0.0028).
(B) Exaggerated LTD in the Fmr1/y is significantly
normalized with 5 mM VU0152100 (KO PAM =
88.7% ± 2.76%, n = 13, *p = 0.0003). VU0152100
treatment has no effect on WT LTD (WT PAM
87.6% ± 3.13%, n = 11, p > 0.999).
(C) Comparison of all four groups (re-plotted from
A and B).
(D) Quantification of the last 10 min of recording
shows a significant rescue of the LTD phenotype in
the Fmr1/y with VU0152100 (ANOVA genotype 3
treatment *p = 0.0191). n = number of animals.
Error bars indicate SEM.veh versus KO PD 1 mM *p = 0.0065; n = 8) (Figure 5B) (Stoll
et al., 2009). This indicates that M4 antagonism worsens the
excessive protein synthesis phenotype in the Fmr1/y hippo-
campus. In contrast, application of the M1-specific antagonist
pirenzepine (75 nM) significantly reduces protein synthesis;
however, this does not correct the difference between WT and
Fmr1/y hippocampi (ANOVA genotype *p = 0.0183, treatment
*p = 0.0119; WT veh versus Pz *p = 0.021; KO versus Pz
*p = 0.048; Figure S6). Thus, inhibition of neither M4 nor M1
normalizes the excessive protein synthesis phenotype in the
Fmr1/y hippocampus.
The robust overexpression of M4 in the Fmr1
/y and its selec-
tive translation downstream of mGlu5 strongly suggested an
involvement in FX pathology. Given that M4 inhibition did not
resolve the protein synthesis phenotype, we wondered whether
the increased synthesis of M4 in Fmr1
/y neurons represented a
compensatory change rather than a direct cause of altered func-
tion. To test this hypothesis, we obtained a highly selective M4
PAM, VU0152100, which enhances the effects of cholinergic ag-
onists on M4 without impacting other mAChRs (Brady et al.,
2008). To test whether M4 enhancement could correct excessive
protein synthesis in the Fmr1/y, we incubated slices in 5 mM
VU0152100, a concentration shown to specifically enhance M4
function in acute brain slices (Pancani et al., 2014). Remarkably,
our results show that VU0152100 significantly reduces the level
of protein synthesis in the Fmr1/y while having no effect on the
WT hippocampus (ANOVA genotype 3 treatment *p = 0.0456,
WT veh versus VU p = 0.658; KO veh versus VU *p = 0.0135;
Figure 5C). The surprising conclusion is that enhancement
of M4, a protein over-translated and overexpressed in the
Fmr1/y hippocampus, corrects the exaggerated protein synthe-
sis phenotype.558 Neuron 95, 550–563, August 2, 2017In addition to exaggerated protein
synthesis, a prominent cellular change
observed in the Fmr1/y is a reduced pro-
duction of cAMP upon stimulation of ad-
enylate cyclase (AC) (Berry-Kravis et al.,
1995; Berry-Kravis and Huttenlocher,
1992; Kelley et al., 2007). The relevanceof this phenotype to the pathology of FX is confirmed by experi-
ments that show that increasing cAMP production corrects
several behavioral measures of learning inmultiple animal models
(Choi et al., 2015, 2016). As the M4 receptor is coupled to the AC/
cAMP pathway, we wondered whether the normalization of pro-
tein synthesis byM4PAMwas due to a change in cAMP signaling.
To test this, we stimulated Fmr1/y and WT slices with the potent
AC activator forskolin (FSK; 50 mM) in the presence of vehicle or
VU0152100 (see STAR Methods; Figure S7). Consistent with
previous studies, we find a significant deficit in FSK-stimulated
cAMP production in the Fmr1/y (ANOVA treatment *p < 0.0001,
genotype 3 treatment *p = 0.0264, WT FSK versus KO
FSK *p = 0.0214, n = 9). However, application of VU0152100
had no effect on the stimulation of cAMP in either WT (p < 0.306)
or Fmr1/y (p < 0.4625, n = 9; Figure S7) slices. These results sug-
gest that although it may be involved in other phenotypes, the
stimulation of cAMP downstream of M4 activation is not respon-
sible for the correction of protein synthesis by M4 PAM.
M4 PAM Corrects the Exaggerated mGluR-LTD
Phenotype in Fmr1–/y CA1
Based on the beneficial effect seen in our biochemical assays,
we wondered whether M4 enhancement could also correct the
exaggerated mGluR-LTD in Fmr1/y CA1. To test this, we per-
formed extracellular recordings in the CA1 region of hippocam-
pal slices ±5 mM VU0152100. LTD was stimulated using 50 mM
S-DHPG, and recordings were performed on hippocampal slices
prepared from WT and Fmr1/y littermates, consistent with
previous work (Barnes et al., 2015). In keeping with previous
findings, our results show a significant enhancement of
mGluR-LTD in vehicle-treated Fmr1/y slices (*p = 0.0028; Fig-
ure 6A) (Huber et al., 2002). However, the application of
Figure 7. M4 PAMCorrects the Exaggerated AGS
Phenotype in the Fmr1–/y Mouse
(A) Time course for AGS experiments.
(B) Injection of VU0152100 significantly reduces the
incidence of AGS in Fmr1/y mice versus vehicle
(Fisher’s exact test *p < 0.0001; KO veh 15/21, KO VU 2/
19, WT veh 1/14, WT PAM 0/14).
(C) VU0152100 reduces severity of AGS in the Fmr1/y
(KO veh wild running 4/21, clonic 11/21, tonic 3/21; KO
VU wild running 1/19, clonic 1/19).VU0152100 resulted in a striking reduction of the exag-
gerated LTD phenotype in Fmr1/y slices (*p = 0.0003) without
affecting LTD magnitude in WT slices. A comparison of LTD in
WT and KO VU0152100-treated slices reveals no significant
difference (Figure 6B). These results show that positive modula-
tion of M4 with VU0152100 resolves exaggerated mGluR-LTD
in the Fmr1/y hippocampus (ANOVA genotype 3 treatment
*p = 0.0191; Figures 6C and 6D), further supporting the idea
that Chrm4 over-translation is a protective mechanism in the
Fmr1/y hippocampus.
M4 PAM Corrects AGS in the Fmr1
–/y Mouse
The positive effects of VU0152100 on the biochemical and elec-
trophysiological phenotypes in Fmr1/y motivated us to test
this treatment in vivo. One of the most robust behavioral pheno-
types observed in the Fmr1/ymousemodel is an increased sus-
ceptibility for AGS (Yan et al., 2005). Treatments that correct this
core phenotype have been found to be effective in ameliorating
many other pathological changes in FX (Michalon et al., 2012;
Osterweil et al., 2013; Yan et al., 2005). To test whether M4
PAM could also correct the AGS phenotype, we injected
Fmr1/y and WT littermates with vehicle (10% DMSO + 10%
Tween-80 in PBS) or 56 mg/kg VU0152100, a dose previously
shown to be effective in reducing aberrant behaviors in mouse
and rat models of psychosis while having no effect on M4 KO
mice (Byun et al., 2014).
To test for AGS, we habituated animals to the testing arena
and then exposed them to a loud (>120 dB) alarm for 2 min
(see STAR Methods; Figure 7A). If seizures occurred, they
were scored for increasing stages of severity: wild running
(pronounced, undirected running, and thrashing), clonic seizure
(violent spasms accompanied by loss of balance), or tonicseizure (postural rigidity in limbs). In accor-
dance with previous work, we find that
vehicle-treated Fmr1/y mice exhibit a
71% incidence of AGS (15/21 animals versus
1/14 animals for WT, *p < 0.0001; Figure 7B).
Remarkably, injection of VU0152100 reduces
this incidence to 10% (2/19 animals, *p <
0.0001). This treatment also reduces the
severity of AGS in Fmr1/y mice, lowering
the incidence of clonic seizures from 38%
(11/21) to 5% (1/19) and eliminating tonic
seizures (Figure 7C). Thus, injection of
VU0152100 significantly reduces both the
incidence and severity of AGS in the Fmr1/y.
Together, our results suggest that positive enhancement of M4
is corrective for multiple Fmr1/y phenotypes.
DISCUSSION
In this study, we sought to tie pathological changes in FX to the
altered translation of specific mRNAs. We chose to do this in
a cell-type-specific way so that we could isolate molecular
changes that could be interrogated at the physiological level.
Our results reveal an increase in the translation of Chrm4 and
Chrm1 mRNA and overexpression of M4 and M1 receptors in
Fmr1/y CA1 neurons. An mGluR-LTD induction protocol stimu-
lates the translation of Chrm4 and expression of M4 in WT CA1
neurons; however, this is saturated in the Fmr1/y hippocampus.
Application of the mGlu5 antagonist MTEP normalizes M4 trans-
lation in the Fmr1/y hippocampus. Surprisingly, although it is
excessively translated in the Fmr1/y, antagonism ofM4 worsens
the protein synthesis phenotype. In contrast, positivemodulation
of M4 using the selective PAM VU0152100 corrects core pheno-
types in the Fmr1/y, including excessive protein synthesis,
exaggerated mGluR-LTD, and increased susceptibility to AGS.
The startling conclusion is that enhancing M4, a protein over-
translated and overexpressed in the Fmr1/y, is a potential new
strategy for correcting FX neuropathology (Figure 8).
Although the TRAP method was developed to identify differ-
ences in the expression of mRNAs in select neuronal popula-
tions, with no distinction between changes driven by translation
or transcription (Doyle et al., 2008; Heiman et al., 2008), we used
this approach to investigate the increased translation that is a
well-known pathophysiology in the Fmr1/y mouse. While we
cannot rule out the possibility that some of the changes we
observe by RNA-seq are due to total mRNA expressionNeuron 95, 550–563, August 2, 2017 559
Figure 8. Potential Model for Correction of FX by M4 PAM
Our results suggest a model whereby M4 is synthesized downstream of mGlu5
in order to negatively regulate protein synthesis and LTD, similar to FMRP. In
FX, the absence of FMRP leads to the excessive synthesis of M4; however, this
is unable to completely compensate for FMRP loss. By enhancing M4 with
VU0152100, protein synthesis, LTD, and other pathological changes are
normalized.differences specific to CA1 neurons, our measurement of total
Camk2a, Chrm1, or Chrm4 mRNAs in FACS-isolated CA1
neurons reveal no differences between Fmr1/y and WT despite
a robust increase in the Fmr1/y TRAP IP (Figures 1E, 3A,
and 3B).
Upon examination of the differentially expressed transcripts,
we discovered that FMRP targets were not enriched in the
Fmr1/y CA1-TRAP fraction (Figure 2D). Further investigation
found that the cumulative distribution of FMRP targets was in
fact reduced in both the starting Input fraction, comprised of total
hippocampal mRNAs, and the CA1-TRAP fraction. While this is
seemingly inconsistent with the mechanism of FMRP as a
repressor of translation, it may be that the loss of FMRP early
in development results in a homeostatic downregulation of
FMRP target mRNAs. It is also possible that loss of FMRP dis-
rupts RNA transport and/or stability (Feng et al., 1997; Tamanini
et al., 1999; Zalfa et al., 2007). Future experiments investigating
how the loss of FMRP results in the eventual dysregulation of
its target mRNAs in the Fmr1/y brain should be particularly
interesting.
A comparative analysis of WT versus Fmr1/y CA1-TRAP re-
vealed 121 differentially expressed transcripts at FDR < 0.1
(Tables S1 and S2). This significance cutoff has been used in pre-560 Neuron 95, 550–563, August 2, 2017vious RNA-seq studies (Cho et al., 2015; Tao et al., 2016), and it
allowed us to include genes that would otherwise have been
excluded as false negatives. Although several genes on this list
may be revealed to be relevant to the synaptic dysfunction in
FX, our unbiased analyses of enriched cellular pathways and
drug interaction targets pointed to Chrm4 as the most obvious
candidate for further investigation (Figures 2G and 2H). The
elevated translation of Chrm4 and Chrm1 in the Fmr1/y hippo-
campus is particularly interesting in light of previously published
studies. In particular, an enhancement of LTD downstream of M1
has been observed in the Fmr1/y hippocampus (Volk et al.,
2007), and some of the behavioral effects seen in the Fmr1/y
are ameliorated by M1 inhibitors (Veeraragavan et al., 2011).
Our results suggest these effects may be due, at least in part,
to an overexpression of M1. In contrast, genetic reduction of
M4 does not appear to correct cognitive deficits (Veeraragavan
et al., 2012), which is consistent with our results showing
that M4 antagonism does not correct protein synthesis in the
Fmr1/y hippocampus (Figure 5B). Whether the enhancement
of M4 can improve cognitive phenotypes in the Fmr1
/y is an
open question; however, the correction of AGS by VU0152100
shows that positive modulation of M4 has a beneficial impact
on brain circuits other than hippocampal CA1 the Fmr1/y
mouse. It will be interesting to investigate the more widespread
effects of M4 PAM on other neuronal populations in the Fmr1
/y
brain.
Our model suggests that the positive modulation of M4 cor-
rects LTD in the Fmr1/y hippocampus by reducing excess pro-
tein synthesis downstream of mGlu5 (Figure 8). Several other
strategies that acutely reduce protein synthesis have also been
shown to correct LTD in the Fmr1/y, includingmGlu5 antagonist,
lovastatin, and lithium (Choi et al., 2011; Michalon et al., 2012;
Osterweil et al., 2013). However, these results are seemingly
inconsistent with studies showing that a complete inhibition of
protein synthesis does not block LTD in the Fmr1/y hippocam-
pus (Nosyreva and Huber, 2006). Although the explanation for
this is currently unknown, the idea that partial inhibition of protein
synthesis differs from a complete block of translation is not
entirely unprecedented. Indeed, previous experiments in iso-
lated synaptic fractions shows that partial block of translation
with low-dose cycloheximide paradoxically increases the trans-
lation of specific mRNAs while inhibiting global translation
(Scheetz et al., 2000). It may be that partial reduction of protein
synthesis in the Fmr1/y restores the translation of the mRNAs
needed to support normal levels of LTD. Alternatively, it is
possible that complete inhibition of protein synthesis in the
Fmr1/y triggers changes in other cellular processes, such as
protein breakdown or mRNA decay, which facilitates LTD
(Harper and Bennett, 2016). To distinguish between these possi-
bilities, further mechanistic studies are needed to fully under-
stand the relationship between mRNA translation and LTD at
Fmr1/y synapses.
Reduction of excessive protein synthesis by inhibiting
mGlu5 or the downstream ERK pathway have been shown to
be successful strategies for correcting pathological changes
in the Fmr1/y mouse (Stoppel et al., 2017). However, recent
attempts to transition mGlu5 antagonists into a clinical setting
have not been successful. Thus, it has become increasingly
important to identify alternative treatment strategies that
more specifically target the dysregulated translation down-
stream of mGlu5. Our results show that M4 is synthesized
downstream of mGlu5, acting as a protective mechanism that
can be enhanced using the M4 PAM VU0152100 (Figure 8). M4
PAMs have been proposed as a treatment for multiple neuro-
psychiatric disorders, including schizophrenia and Alzheimer’s
disease (Jones et al., 2012). Studies in rodents have shown
that the administration of M4 PAMs result in pro-cognitive
effects,without causing negative side effects associated with
less specific cholinergic modulators (Brady et al., 2008; Bubser
et al., 2014). Thus, M4 PAMs may represent a novel treatment
option.
Perhaps more importantly, our study shows that not all exces-
sively translating mRNAs in FX are contributing to pathological
changes. Many studies have focused on reducing the expres-
sion of FMRP target mRNAs in the Fmr1/y, following the
assumption that this will correct phenotypes. However, our re-
sults show that the reverse approach is successful in the case
ofM4. This raises the possibility that other excessively translating
mRNAs may similarly be protective adaptations. This does not
argue against the idea that excessive protein synthesis is patho-
logical, but it does suggest that the specificmRNAs translating in
excess are important to evaluate. Indeed, enhancing the function
of certain over-synthesized proteins may be an overlooked
approach to correcting FX.STAR+METHODS
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Clarity Western ECL Substrate Bio-Rad 1705061
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Oligonucleotides
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Software and Algorithms
GraphPad Prism v.6 GraphPad Software N/A
Microsoft Excel Microsoft N/A
R R-project N/A
STAR 2.4.0i Dobin et al., 2013 N/A
featureCounts 1.4.6-p2 Liao et al., 2014 N/A
FlowjJ v.10 FlowJo N/ACONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Emily
Osterweil (emily.osterweil@ed.ac.uk). The CA1-TRAP mouse (GM391-TRAP) was obtained from a repository at Jackson Labs,
and antibodies for TRAP (HtzGFP-19F7 and HtzGFP-19C8) were obtained from Sloan Memorial Kettering Centre, after establishing
MTAs with the laboratory of Prof. Nathaniel Heintz at The Rockefeller University.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
Fmr1-/y and CA1-TRAP mice (created by http://gensat.org/ and obtained from Jackson Labs with permission from Nathanial Heintz)
were bred on the JAX C57BL/6J background. All experiments were carried out using male littermate mice aged P25-32, and studied
with the experimenter blind to genotype. Fmr1-/y and WT littermates were bred using Fmr1+/ females and JAX C57BL/6J males.
Fmr1-/y-TRAP and WT-TRAP littermates were bred using Fmr1+/ females and CA1-TRAP homozygous males.
All mice were naive to drug and behavioral testing. Mice were group housed (6 maximum) in conventional non-environmentally
enriched cages with unrestricted food and water access and a 12h light-dark cycle. Room temperature was maintained at 21 ±
2C. Animal husbandry was carried out by University of Edinburgh technical staff. All procedures were in performed in accordance
with ARRIVE guidelines and the regulations set by the University of Edinburgh and the UK Animals Act 1986.
METHOD DETAILS
Confocal Imaging
CA1-TRAP mice were perfused with 4% PFA and 50 mm coronal vibratome sections mounted with Vectashield (Vector labs) and
imaged by confocal microscope (Nikon A1R FILM) in collaboration with the IMPACT facility at the University of Edinburgh.
TRAP
Briefly, CA1-TRAP WT and Fmr1-/y male littermates (P25-32) were decapitated and hippocampi rapidly dissected in ice cold PBS.
Hippocampi were homogenized in ice-cold lysis buffer (20 mM HEPES, 5 mM MgCl2, 150 mM KCl, 0.5 mM DTT, 100 mg/ml cyclo-
hexamide, RNase inhibitors and protease inhibitors) using dounce homogenizers, and samples centrifuged at 1,000 x g for 10 min to
remove large debris. Supernatants were then extracted with 1% NP-40 and 1% DHPC on ice, and centrifuged at 20,000 x g forNeuron 95, 550–563.e1–e5, August 2, 2017 e2
20 min. A 50 mL sample of supernatant was removed for use as Input, and the rest incubated with streptavidin/protein L-coated
Dynabeads (Life Technologies) bound to anti-GFP antibodies (HtzGFP-19F7 and HtzGFP-19C8, Memorial Sloan Kettering Centre)
overnight at 4C with gentle mixing. Anti-GFP beads were washed with high salt buffer (20 mM HEPES, 5 mM MgCl2, 350 mM
KCl, 1% NP-40, 0.5 mM DTT and 100 mg/ml cyclohexamide) and RNA was eluted from all samples using Absolutely RNA Nanoprep
kit (Agilent) according to the manufacturer’s instructions. RNA yield was quantified using RiboGreen (Life Technologies) and RNA
quality was determined by Bioanalyzer analysis.
RT-qPCR
RNA for each sample was converted into cDNA using Superscript VILO cDNA Synthesis Kit (Life Technologies) and RT-qPCR was
performed using Quantitect SYBRgreen qPCR master mix (QIAGEN) according to the manufacturer’s instructions. Samples were
prepared in triplicate in 96-well reaction plates and run on a StepOne Plus (Life Technologies). For TRAP analysis, each sample
was normalized to Gapdh, and then each IP was normalized to the corresponding Input sample. For FACS analyses, all samples
were first normalized to Gapdh, and then each GFP-positive or GFP-negative sample was normalized to the corresponding
sample from all cells. Primers used for RT-qPCR are as follows: Gapdh (F- GACAACTTTGGCATTGTGGA, R- CATCATACTTGGCA
GGTTTCTC); Camk2a (F- GGAATCTTCTGAGAGCACCA, R- CACATCTTCGTGTAGGACTC); Wfs1 (F- CCATCAACATGCTCC
CGTTC, R- GGGTAGGCCTCGCCATACA); Gad1 (F- CACAGGTCACCCTCGATTTTT, R- ACCATCCAACGATCTCTCTCATC); Gfap
(F- TCCTGGAACAGCAAAACAAG, R- CAGCCTCAGGTTGGTTTCAT); Chrm1 (F- TCTCTGAATGCTGGAAGTAAAGA, R- GAGACCC
TAGATTCAGTCCCA); Chrm3 (F- AGGGCTGACTACTTAATCTTGGATA, R- TGCAAGGTCATTGTGACTCTC); Chrm4 (F- CAGCGG
AGCAAGACAGAAG, R- GCACAGACTGATTGGCTGAG); Chrm5 (F- TTAAGCTGCTGCTTCTCTGC, R- TTTCCAGAGGAGTTGCTA
AGG); Arc (F- CAGGGGTGAGCTGAAGCCACAAA, R- CCATGTAGGCAGCTTCAGGAGAAGAGAG).
RNA-Seq
RNA with RIN > 7 was prepared for RNA-seq using the RNaseq Ovation V2 kit (Nugen), according to manufacturer’s instructions.
Samples were sent to Oxford Genomics Centre for sequencing using Illumina HiSeq 2500 or HiSeq 4000. Sequencing reads (50
or 75 bp, paired end) were mapped to the Mus musculus primary assembly (Ensembl release v80) using STAR 2.4.0i (Dobin et al.,
2013). Reads that were uniquely aligned to annotated genes were counted with featureCounts 1.4.6-p2 (Liao et al., 2014). Differential
expression analyses were performed using DESeq2 1.12.4 with betaPrior = FALSE (Love et al., 2014). TPM (transcripts per million)
values were determined using Salmon 0.7.2 at the transcript level and gene TPMs were calculated by adding the values of all tran-
scripts for each gene (Patro et al., 2017). Cell type specificity analyses were performed with Enrichr using the Allen_brain_atlas_up
library. A heatmap of differentially expressed genes was created using pheatmap 1.0.8. TPM values were normalized to the average
TPM of the WT and the values were scaled before creating the heatmap. GO analyses were performed with Enrichr (http://amp.
pharm.mssm.edu/Enrichr/) (Chen et al., 2013) using theGO_molecular_function 2015 library. Number of drugs interactingwith Genes
differentially regulated in the Fmr1-/y CA1-TRAP were quantified using the Drug Gene Interaction database (http://dgidb.genome.
wustl.edu/) (Griffith et al., 2013).
pClan Analysis
Genes differentially expressed in the Fmr1-/y CA1-TRAP were categorized into pClans using the Pfam database (EMBL_EBI, http://
pfam.xfam.org/). An updated list of FMRP targets (Jen Darnell, personal communication) was adjusted to include only genes iden-
tified in at least one CA1-TRAP IP (TPM > 0). Adjusted FMRP targets were also categorized into pClans using the Pfam database.
pClans from these lists were compared with the pClans from the background list of all CA1-TRAP genes (TPM > 0 in any one sample)
to identify enriched pClans. pClan enrichment (over background CA1-TRAP genes) was determined by Fisher’s Exact test (p < 0.01).
Significantly enriched pClans were compared between Fmr1-/y CA1-TRAP genes and FMRP targets.
FMRP Target Analysis
Genes with DESeq2 normalized counts similar to FMRP targets were selected for comparison from the differentially expressed Input
and CA1-TRAP fractions (Input: between 102.5 and 104.25; CA1-TRAP: between 102.75 and 104.75). Cumulative distributions of log2
fold change were compared between FMRP targets and either all genes within the same abundance (Figure 2) or to 5 randomly
selected gene sets of the same number (Figure S3). Significance determined by K-S test. In addition, the proportion of up- and down-
regulated genes was compared and significance determined by Fisher’s exact test (Figure S3).
Hippocampal Slice Preparation
Hippocampal slices were prepared from male littermate WT and Fmr1-/y mice (P25-32), in an interleaved fashion, with the experi-
menter blind to genotype as described previously (Osterweil et al., 2010). Briefly, mice were anaesthetized with isofluorane and
the hippocampus was rapidly dissected in ice-cold ACSF (124 mM NaCl, 3 mM KCl, 1.25 mM NaH2PO4, 26 mM NaHCO3, 10 mM
dextrose, 1 mMMgCl2 and 2 mMCaCl2, saturated with 95%O2 and 5%CO2). Slices (500 mm thick) were prepared using a Stoelting
Tissue Slicer and transferred into 32.5C ACSF (saturated with 95%O2 and 5%CO2) within 5 min. Slices were incubated in ACSF for
4 hr to allow for recovery of protein synthesis. For DHPG stimulation, slices were transferred into ACSF containing 50 mM S-DHPG
(Sigma) or vehicle (ddH2O) for 5 min, before being transferred to fresh ACSF to recover for an additional 25 or 55 min. For MTEPe3 Neuron 95, 550–563.e1–e5, August 2, 2017
stimulations, slices were transferred to ACSF containing 10 mM MTEP (Tocris) or vehicle (ddH2O) for 1.5 hr. Slices were either pro-
cessed for TRAP or immunoblotted.
Synaptoneurosome Preparation
Hippocampal slices were prepared as above, then homogenized in ice-cold homogenization buffer (10 mM HEPES, 2 mM EDTA,
2 mM EGTA, 150 mM NaCl) in 2 mL Dounce homogenizers. Homogenates were filtered through a 100 mm filter (Millipore), followed
by a 5 mmfilter (Millipore). Homogenates were centrifuged at 10000 x g for 10 min and the supernatant was discarded. The pellet was
re-suspended in lysis buffer (50 mM HEPES, 5 mM EDTA, 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS)
and protein concentrations were determined using BioRad DC (BioRad). Samples were boiled in Laemmli sample buffer for
immunoblotting.
FACS
Hippocampal slices were prepared and recovered as above. CA1 wasmicro-dissected and incubated in ACSF with papain (20 U/ml;
Sigma-Aldrich) for 45 min at 37C with 5% CO2. Tissue was dissociated using a fire polished glass pipette and filtered using a 70 mm
cell sieve. A sample of single cell dissociate was used to isolate RNA from all cell types prior to sorting. Cell sorting was performed on
FACSAria II (BD bioscience) using DAPI as a live/deadmarker. Fromeachmouse, an average of 1500-GFP positive neurons or 10,000
GFP-negative cells were collected in RNA extraction buffer. For immunostaining, cell dissociate was fixedwith 4%PFA, filteredwith a
70 mm cell sieve, and blocked with 1.5% FCS in PBS for 10 min. Primary antibodies to M1 (M9808, Sigma), M4 (ab77956, Abcam), or
M3 (GTX111637, GeneTex) were applied for 30 min at room temperature. Alexa 594 conjugated secondary antibody (Thermo Fisher)
was applied for 10 min at room temperature. Flow analyses were performed using the LSRFortessa (BD bioscience) and the data
analyzed using FlowJo software in collaboration with the QMRI flow cytometry core facility at the University of Edinburgh. To correct
for the experiment-to-experiment signal intensity variance, each value obtained in an experiment was normalized by the average
value obtained from all cells in that experiment. All staining and analysis were performed blind to genotype.
Immunoblotting
Hippocampal slices were homogenized in ice-cold homogenization buffer (10 mM HEPES pH 7.4, 2 mM EDTA, 2 mM EGTA,
1% Triton X-100, protease inhibitors and phosphatase inhibitors). Samples were boiled in Laemmli sample buffer and resolved on
SDS-PAGE gels before being transferred to nitrocellulose and stained for total protein using the Memcode Reversible staining kit
(Pierce). Membranes were blocked with 5% BSA in TBS + 0.1% Tween-20 for 1h, then incubated in primary antibody overnight at
4C (M4 1:500 ab77956, Abcam; M1 1:1000 M9808, Sigma; M3 1:1000 GTX111637, Genetex). Membranes were then incubated
with HRP-conjugated secondary antibodies for 30 min (Cell Signaling), developed with Clarity ECL (BioRad), and exposed to film.
Densitometry was performed on scanned blot films and quantified using ImageStudio Lite (Li-Cor). Densitometry data was normal-
ized to total protein, which was quantified using scanned images of total protein staining and quantified using FIJI. To correct for blot-
to-blot variance, each signal was normalized to the average signal of all lanes on the same blot. All gels were loaded and analyzed
blind to genotype and treatment.
Metabolic Labeling
Hippocampal slices were prepared and recovered as above, then incubated in ACSF containing 25 mM Actinomycin D (Tocris) plus
either vehicle (0.002% DMSO in ddH2O) or 75 nM pirenzepine (Tocris), 0.5 mM PD102807, 1 mM PD102807 (Tocris) or 5 mM
VU0152100 (Sigma) for 30 min. Slices were then transferred to fresh ACSF containing 10 mCi/ml 35S-Met/Cys (Perkin Elmer) with
vehicle or drugs as listed above for another 30 min. After labeling, slices were homogenized in ice-cold buffer (10 mM HEPES
pH 7.4, 2 mM EDTA, 2 mM EGTA, 1% Triton X-100, protease inhibitors and phosphatase inhibitors). To precipitate proteins, homog-
enateswere incubated in trichloroacetic acid (TCA: 10%final) for 10min on ice before being centrifuged at 16,000 rpm for 10min. The
pellet was washed in ice-cold ddH2O and re-suspended in 1 N NaOH until dissolved, and the pH was re-adjusted to neutral using
0.33 N HCl. Triplicates of each sample were added to scintillation cocktail and read with a scintillation counter. Protein concentration
of each sample was measured using BioRad DC (BioRad). Averaged triplicate counts per minute (CPM) values were divided by pro-
tein concentrations, resulting in CPM per mg protein. To control for daily variation in incorporation rate, the values obtained on each
day were normalized to the 35S-Met/Cys ACSF used for incubation, and the average incorporation of all slices analyzed in that exper-
iment. For autoradiography, slice homogenates were resolved on SDS-PAGE gels, transferred to nitrocellulose and exposed to a
phosporimaging screen (GE Healthcare). Phosphorimages were acquired using a Typhoon scanner (GE Healthcare) and compared
to total protein staining of the same membrane.
cAMP Concentration
Hippocampal slices were prepared and recovered as above, then incubated in ACSF containing 5 mM VU0152100 or vehicle (0.01%
DMSO) for 1 hr. Slices were then transferred to fresh ACSF containing 50 mM forskolin (Sigma), 5 mMVU0152100 + 50 mM forskolin, or
vehicle (0.01% DMSO) for 30 min. After stimulations slices were frozen on dry ice and immediately homogenized in ice-cold homog-
enization buffer (HBSS (Thermo Fisher, 14175053), 1%Triton X-100, 0.5mM IBMX (Sigma)). Samples were centrifuged at 16,000 rpm
for 5 min and 5 mL of supernatant was used to measure cAMP concentrations following the manufacturer’s instructions (CisBio,Neuron 95, 550–563.e1–e5, August 2, 2017 e4
62AM4PEB). Protein concentration of each sample was measured using BioRad DC (BioRad). Averaged triplicate cAMP concentra-
tions (nM) were divided by protein concentrations, resulting in nM cAMP per mg protein.
Electrophysiology
Horizontal hippocampal slices (400 mM)were prepared from Fmr1-/y andWT littermates (P25-32) in ice-cold dissection buffer (86 mM
NaCl, 25 mM KCl, 1.2 mM NaH2PO4, 25 mM NaHCO3, mM 20 glucose, 0.5 mM CaCl2, 7 mM MgCl2, saturated with 95% O2 and
5% CO2) and an incision made through CA3. Slices were recovered for at least 2 hr at 30
C in ACSF (124 mM NaCl, 5 mM KCl,
1.25 mM NaH2PO4, 26 mM NaHCO3, 10 mM glucose, 2 mM CaCl2; 1 mMMgCl2, saturated with 95% O2 and 5% CO2) before being
transferred to a submersion chamber heated to 30C and perfused with ACSF containing either DMSO vehicle or VU0152100 (5 mM).
Field excitatory postsynaptic potentials (fEPSP) were evoked by applying a current pulse to the Schaffer collateral pathway every 30 s
with a bipolar stimulating electrode and recording with an extracellular electrode (1-3 MU) in stratum radiatum of hippocampal CA1.
Following a 20 min stable baseline, LTD was induced by the application of S-DHPG (50 mM; 5 min) in the presence of either vehicle
(0.002% DMSO in ddH2O) or VU0152100 (5 mM), which was present for the duration of the recording (55 min post DHPG washout).
Themagnitude of LTDwas calculated from average fEPSP slope during the last 10min of recording relative to fEPSP slope during the
20 min baseline.
AGS
Experiments were performed essentially as previously described (Osterweil et al., 2013). Naive male P23-25 mice were weighed and
injected intraperitoneally (i.p.) with 56 mg/kg VU0152100 or vehicle (10% DMSO + 10% Tween-80 in PBS) and transferred to a quiet
(< 60 dB ambient sound) room for 1 hr. Mice were then transferred to a transparent plastic test chamber and, after 1 min of habitu-
ation, exposed to a stimulus of > 120 dB (recorded sampling of a modified personal alarm, Radioshack model 49-1010) for 2 min.
Each testing session contained mice from both genotype and treatment groups, tested with the experimenter blind to genotype
and treatment. For each group, incidence of the following stages of AGS was calculated: wild running (WR; pronounced, undirected
running and thrashing), clonic seizure (violent spasms accompanied by loss of balance), or tonic seizure (postural rigidity in limbs).
Any animal that reached tonic seizure was immediately humanely euthanized.
QUANTIFICATION AND STATISTICAL ANALYSIS
For qPCR, biochemistry and electrophysiology experiments, outliers > 2 SD from the mean were removed and significance (p < 0.05)
was determined by repeated-measures two-way ANOVA using GraphPad Prism software. If significant effects were found by
ANOVA, post hoc analyses were performed to compare individual groups using two-tailed paired or unpaired t test with Bonferroni
correction for multiple comparisons. For AGS experiments significance was determined by Fisher’s Exact Test. Detailed results of all
statistical analyses can be found in the figure legends.
DATA AND SOFTWARE AVAILABILITY
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